Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
474.5 ^USD	+0.89%		+1.23%	+16.61%

02/07	FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	MT
02/07	Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	DJ

Vertex Pharmaceuticals Incorporated Provides Revenues Guidance for the Full Year of 2020

January 31, 2020 at 02:31 am IST

Vertex Pharmaceuticals Incorporated provided revenues guidance for the full year of 2020. The company provides full-year 2020 total product revenue guidance in the range of $5.1 billion to $5.3 billion.

Latest news about Vertex Pharmaceuticals Incorporated

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	02/07	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	02/07	DJ
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	02/07	CI
Verve Therapeutics, Inc. Announces Board and Committee Appointments	28/06	CI
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	27/06	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	25/06	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	24/06	MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes	22/06	MT
Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes	22/06	CI
Vertex Pharmaceuticals Has Pricing Accord for Cystic Fibrosis Drugs With UK National Health Service	20/06	MT
Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465	17/06	MT
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials	14/06	MT
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on CASGEVY (Exagamglogene Autotemcel)	14/06	CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,089,840, According to a Recent SEC Filing	14/06	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,483,664, According to a Recent SEC Filing	14/06	MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM	11/06
RBC Adjusts Price Target on Vertex Pharmaceuticals to $421 From $424	11/06	MT
Vertex Pharmaceuticals Says Phase 3 Data Show Trikafta Improves Lung Function in Cystic Fibrosis Patients	07/06	MT
Vertex Pharmaceuticals Incorporated Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA	07/06	CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing	06/06	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing	06/06	MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 04:00 PM	05/06
Vertex Pharmaceuticals Insider Sold Shares Worth $2,033,159, According to a Recent SEC Filing	04/06	MT
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480	31/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing	31/05	MT

Chart Vertex Pharmaceuticals Incorporated

Duration

Period

Chart Vertex Pharmaceuticals Incorporated

More charts

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

Biotechnology & Medical Research

Calendar

02/08/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

474.6 USD

Average target price

468.3 USD

Spread / Average Target

-1.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.56B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B
INSMED INCORPORATED	+125.88%	11.29B

Bio Therapeutic Drugs